Article

Allergan to cut 1,500 jobs

Allergan has announced that, alongside its second-quarter financial results, it will reduce its workforce by about 1,500 employees-about 13% of its current global headcount-as part of efforts to boost stockholder value.

 

Irvine, CA-Allergan has announced that, alongside its second-quarter financial results, it will reduce its workforce by about 1,500 employees-about 13% of its current global headcount-as part of efforts to boost stockholder value.

The company said Monday that the restructuring, along with other measures, would lead to savings of about $475 million in 2015.

The savings “will come from efficiencies and reductions in spend across the commercial organization, general and administrative functions, manufacturing and the research and development (R&D) organization,” the company said.

Allergan said the job cuts, along with the elimination of about 250 vacant positions, follow a review of its operations, including its portfolio of R&D projects. The company said that all pharmaceutical research programs in the clinic would continue, while any reductions in discovery programs “will not impact approvals within the strategic plan period” through 2019.

 

“With continuing strong momentum, Allergan recorded the strongest increase in absolute dollar sales in any quarter in our history, and again delivered sales and earnings per share growth above the high end of our expectations,” said David. E.I. Pyott, Allergan chief executive officer.

Allergan’s product sales in the second quarter rose 15.9% year-over-year to $1.8 billion, surpassing analyst estimates, while sales of Botox increased 12.9% to $579.4 million. Furthermore, net income reached $417.2 million, versus $359.9 million in the same period of last year.

For the full year, Allergan said it expects total product sales between $6.9 billion and $7.05 billion.

 

For more articles in this issue of Ophthalmology Times eReport, click here.

 

 

To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.